Ceruvia Raises $8 Million to Complete Integrated Phase 1/2 Trial of Proprietary Non-Hallucinogenic LSD Analog for Cluster Headache

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ceruvia-Lifesciences

More Like This

PR Newswire associated0

Ceruvia Founder and CEO, Carey Turnbull, Featured in New Book "Psychedelic Outlaws"

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference